☆ 4.8 Article

Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial

FRONTIERS IN IMMUNOLOGY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Cardiac & Cardiovascular Systems

Open versus hybrid versus totally minimally invasive Ivor Lewis esophagectomy: Systematic review and meta-analysis

Camila Bras Harriott et al.

Summary: Hybrid and totally minimally invasive esophagectomy are associated with lower rates of overall morbidity, reduced postoperative mortality, and shorter length of hospital stay compared with open esophagectomy. Totally minimally invasive esophagectomy has lower mortality rates and shorter length of hospital stay compared with hybrid esophagectomy.

JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2022)

添加到收藏夹

Article Medicine, Research & Experimental

Combining serum inflammation indexes at baseline and post treatment could predict pathological efficacy to anti-PD-1 combined with neoadjuvant chemotherapy in esophageal squamous cell carcinoma

Xinke Zhang et al.

Summary: This study analyzed data from ESCC patients receiving anti-PD-1 combined with neoadjuvant chemotherapy and found that NLR, LMR, PLR, and SII can predict therapeutic response. Combining these parameters can improve prediction ability.

JOURNAL OF TRANSLATIONAL MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

Y. Doki et al.

Summary: In patients with advanced esophageal squamous-cell carcinoma, both first-line treatment with nivolumab plus chemotherapy and first-line treatment with nivolumab plus ipilimumab resulted in significantly longer overall survival than chemotherapy alone, with no new safety signals identified.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Oncology

Neoadjuvant chemotherapy with liposomal paclitaxel plus platinum for locally advanced esophageal squamous cell cancer: Results from a retrospective study

Wenzhong Wang et al.

Summary: This study analyzed the efficacy and safety of neoadjuvant chemotherapy with liposomal paclitaxel plus platinum in patients with locally advanced resectable esophageal squamous cell carcinoma (ESCC). The results showed that this regimen can improve the resection rate, survival rate, and tumor down-staging effect, with good safety profile.

THORACIC CANCER (2022)

添加到收藏夹

Article Oncology

Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma

Weixiong Yang et al.

Summary: This study evaluated the safety and feasibility of using PD-1 blockade in combination with chemotherapy as neoadjuvant therapy in patients with resectable esophageal squamous cell carcinoma (ESCC). The results showed that this neoadjuvant treatment regimen had manageable side effects and induced an objective response in 90.5% of patients, demonstrating its antitumor efficacy in resectable ESCC.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Article Medicine, General & Internal

Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial

Zhihao Lu et al.

Summary: This study evaluated the efficacy of sintilimab in combination with chemotherapy for patients with unresectable locally advanced, recurrent, or metastatic oesophageal squamous cell carcinoma. The results demonstrated significant improvements in overall survival and progression free survival with sintilimab plus cisplatin and paclitaxel compared to placebo plus chemotherapy. Similar benefits were seen with sintilimab plus cisplatin and 5-fluorouracil.

BMJ-BRITISH MEDICAL JOURNAL (2022)

添加到收藏夹

Article Oncology

Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma

Jun Liu et al.

Summary: The study demonstrated the safety and efficacy of camrelizumab plus neoadjuvant chemotherapy in locally advanced esophageal squamous cell carcinoma, achieving a high rate of pathologically complete response and manageable adverse events.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Article Oncology

Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)

Chengqiang Li et al.

Summary: This study investigated the safety and efficacy of preoperative pembrolizumab combined with chemoradiotherapy in resectable oesophageal squamous cell carcinoma patients. The results showed that this treatment was safe and induced a pathological complete response in 55.6% of the tumors.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Review Engineering, Biomedical

Recent Advances in Cell Membrane-Derived Biomimetic Nanotechnology for Cancer Immunotherapy

Faisal Raza et al.

Summary: Immunotherapy in cancer treatment is being significantly impacted by advancements in biomimetic nanotechnology. The challenges surrounding cancer nanomedicine have led to a push for innovative approaches, such as biomimetic nanoparticles, to improve the delivery and effectiveness of immunotherapeutics for cancer. These strategies show promise in addressing issues related to the tumor microenvironment, patient heterogeneity, and immunotoxicity.

ADVANCED HEALTHCARE MATERIALS (2021)

添加到收藏夹

Article Oncology

The safety and efficacy of neoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma

Dijian Shen et al.

Summary: The study evaluated the efficacy and safety of PD-1 inhibitor in neoadjuvant chemotherapy for locally advanced ESCC, showing a high pCR rate and R0 resection rate with low toxicity. Long-term efficacy of this novel treatment should be confirmed with longer follow-up and prospective trials.

JOURNAL OF GASTROINTESTINAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial

Ben M. Eyck et al.

Summary: The preoperative chemoradiotherapy regimen according to CROSS study has shown to have a long-term overall survival benefit for patients with locally advanced resectable esophageal or junctional cancer, with a stable effect observed up to 10 years of follow-up.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

Ronan J. Kelly et al.

Summary: In patients with resected esophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy, adjuvant therapy with nivolumab significantly improved disease-free survival compared to placebo.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Surgery

Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma A Randomized Clinical Trial

Hao Wang et al.

Summary: The study compared the safety and long-term survival outcomes of neoadjuvant chemoradiotherapy (nCRT) followed by minimally invasive esophagectomy (MIE) with neoadjuvant chemotherapy (nCT) followed by MIE for locally advanced esophageal squamous cell carcinoma (ESCC) patients. The initial results showed that nCRT followed by MIE had similar safety and better pathologic outcomes compared to nCT followed by MIE for treating locally advanced ESCC.

JAMA SURGERY (2021)

添加到收藏夹

Article Medicine, General & Internal

Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial

Huiyan Luo et al.

Summary: The addition of camrelizumab to chemotherapy significantly improved overall survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma. This treatment strategy could enhance the overall survival rate of patients.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

Jong-Mu Sun et al.

Summary: This study aimed to evaluate the antitumor activity of pembrolizumab plus chemotherapy versus chemotherapy alone as first-line treatment in advanced esophageal cancer. Results showed that pembrolizumab plus chemotherapy significantly improved overall survival and progression-free survival in patients with esophageal squamous cell carcinoma.

LANCET (2021)

添加到收藏夹

Review Medicine, General & Internal

Inflammation and nutrition-based biomarkers in the prognosis of oesophageal cancer: a systematic review and meta-analysis

Yan Jiang et al.

Summary: This meta-analysis evaluated the predictive value of various biomarkers in oesophageal cancer prognosis, with CAR and mGPS having the highest AUC values. Clinical indicators such as NLR, PLR, LMR, PNI, SII, CAR, GPS, and mGPS showed moderate predictive ability in overall survival, disease-free survival, and cancer-specific survival of oesophageal cancer. Pretreatment levels of CAR and mGPS were particularly effective in predicting 5-year overall survival for oesophageal cancer.

BMJ OPEN (2021)

添加到收藏夹

Letter Dermatology

Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies

A. Freites-Martinez et al.

ACTAS DERMO-SIFILIOGRAFICAS (2021)

添加到收藏夹

Meeting Abstract Oncology

A study of neoadjuvant sintilimab combined with triplet chemotherapy of lipo-paclitaxel, cisplatin, and S-1 for resectable esophageal squamous cell carcinoma (ESCC)

Y. Gu et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients

Vincenzo Graziano et al.

BREAST (2019)

添加到收藏夹

Article Oncology

Concurrent liposomal paclitaxel and cisplatin chemotherapy improved outcomes for locally advanced esophageal squamous cell carcinoma treated with intensity-modulated radiotherapy

Shu Liu et al.

ANNALS OF TRANSLATIONAL MEDICINE (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Epidemiology of Esophageal Squamous Cell Carcinoma

Christian C. Abnet et al.

GASTROENTEROLOGY (2018)

添加到收藏夹

Article Oncology

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Freddie Bray et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2018)

添加到收藏夹

Article Oncology

Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial

Hong Yang et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Cancer of the Esophagus and Esophagogastric Junction: An Eighth Edition Staging Primer

Thomas W. Rice et al.

JOURNAL OF THORACIC ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy

Ghayathri Jeyakumar et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)

添加到收藏夹

Article Oncology

Cancer Statistics in China, 2015

Wanqing Chen et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2016)

添加到收藏夹

Article Oncology

RECIST 1.1-Update and clarification: From the RECIST committee

Lawrence H. Schwartz et al.

EUROPEAN JOURNAL OF CANCER (2016)

添加到收藏夹

Article Nanoscience & Nanotechnology

Development of paclitaxel-loaded liposomal nanocarrier stabilized by triglyceride incorporation

Soon-Seok Hong et al.

INTERNATIONAL JOURNAL OF NANOMEDICINE (2016)

添加到收藏夹

Article Oncology

Neoadjuvant Chemotherapy versus Chemoradiation Prior to Esophagectomy: Impact on Rate of Complete Pathologic Response and Survival in Esophageal Cancer Patients

Pamela Samson et al.

JOURNAL OF THORACIC ONCOLOGY (2016)

添加到收藏夹

Article Gastroenterology & Hepatology

Guidelines for Diagnosis and Treatment of Carcinoma of the Esophagus April 2012 edited by the Japan Esophageal Society

Hiroyuki Kuwano et al.

ESOPHAGUS (2015)

添加到收藏夹

Review Medicine, General & Internal

Esophageal Carcinoma

Anil K. Rustgi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

添加到收藏夹

Article Oncology

Three-arm Phase III Trial Comparing Cisplatin Plus 5-FU (CF) Versus Docetaxel, Cisplatin Plus 5-FU (DCF) Versus Radiotherapy with CF (CF-RT) as Preoperative Therapy for Locally Advanced Esophageal Cancer (JCOG1109, NExT Study)

Kenichi Nakamura et al.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2013)

添加到收藏夹

Article Oncology

A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy

Jing Huang et al.

MEDICAL ONCOLOGY (2013)

添加到收藏夹

Article Oncology

A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907)

Nobutoshi Ando et al.

ANNALS OF SURGICAL ONCOLOGY (2012)

添加到收藏夹

Article Oncology

A Phase II Study of Paclitaxel and Nedaplatin as First-line Chemotherapy in Patients with Advanced Esophageal Cancer

Weiguo Cao et al.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2009)

添加到收藏夹

Article Pharmacology & Pharmacy

Enhanced solubility and stability of PEGylated liposomal paclitaxel: In vitro and in vivo evaluation

Tao Yang et al.

INTERNATIONAL JOURNAL OF PHARMACEUTICS (2007)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.